On 23-24 January 2017, the LINK programme held its first full team meeting hosted by Professor Bob Snow in Nairobi, Kenya. This was a valuable opportunity for the London and Nairobi-based team members to meet for an update on the programme and to jointly plan activities going forward.
A feedback dissemination meeting on the just concluded Nairobi newborn study took place on Monday 30th January and was attended by 75 delegates. Discussions were on: routine newborn care in newborn units, infrastructure and services available in health facilities, accessibility of drugs, newborn care in the maternity wards, material and human resource capacity, utilization of inpatient newborn services; and the quality of existing services.
In a first, scientists used computer simulations to identify the vaccines most likely to be effective against respiratory syncytial virus (RSV), the most common cause of infant severe pneumonia worldwide.
Bangkok, 2 February 2017 – A lineage of multidrug resistant P. falciparum malaria has widely spread and is now established in parts of Thailand, Laos and Cambodia, causing high treatment failure rates for the main falciparum malaria medicines, artemisinin combination therapies (ACTs), according to a study published today in The Lancet Infectious Diseases.
Bangkok, 16 Jan 2017 – In the largest study of its kind, a team of researchers led by MORU and WWARN in Bangkok developed a pharmacokinetic model that enabled a revised dose regimen to safely treat all malaria patients including young children with dihydroartemisinin-piperaquine (DP), a widely used antimalarial and a first-line treatment against malaria recommended by the World Health Organization (WHO).
Hosted by University Sao Paulo Medical School at the Centro de Convenções Rebouças ZIKAlliance, the multinational and multidisciplinary consortium coordinated by Inserm, the French National Institute of Health and Medical Research, and created in response to a Horizon 2020 funding call by the European Commission’s Directorate-General Research and ...
Prof Paul Newton, Director of LOMWRU and Head of the Medicine Quality Group at the Infectious Diseases Data Observatory IDDO, explains the history of falsified medicines and highlights what needs to be done to avert a problem that threatens us all.
The Epidemic diseases Research Group Oxford ERGO showcased their recent research at the Natural History Museum in Oxford last Saturday. Younger and older visitors to the stall were welcomed by real live vectors of the diseases (camels, bats and mosquitoes) then asked if they would like to try one of the personal protective equipment (PPE) suits worn by the group during their recent clinical trial to find a drug to treat Ebola. The groups research on Ebola and Zika virus was also discussed.